Disease · EFO_1001243

wheat allergic reaction

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. wheat allergic reaction. Diseases, record EFO_1001243. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001243

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: wheat allergic reaction; Open Targets
Open Targets ID: EFO_1001243; Open Targets
Other names: Wheat Hypersensitivity, wheat allergy; Open Targets
Disease Ontology: DOID:3660; Disease Ontology
MeSH: D021182; MeSH
Highest stage of its drugs: Phase 3, for its one drug, from ClinicalTrials.gov; Open Targets

Drugs1

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here
OMALIZUMAB	CHEMBL1201589	Antibody	Phase 3	ClinicalTrials.gov	3	3	3

Source Drugs and targets

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
IGHE	Immunoglobulin heavy constant epsilon	1	Ig epsilon chain C region inhibitor	Phase 3	https://conductscience.org/library/genes/3497

Source Drugs and targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03881696	Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants	Phase 3	458	2024-06-04	Peanut Allergy, Multi-food Allergy	OMALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03181009	Multi OIT to Test Immune Markers After Minimum Maintenance Dose	Phase 2	60	2019-09-20	Food Allergy	OMALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT06103656	E-B-FAHF-2, Multi OIT and Xolair for Food Allergy	Phase 2	33		Food Allergy	OMALIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Omalizumab vs Placebo for Omalizumab: deaths from any cause	0 of 120	0 of 60	180	NCT03881696	Trial comparisons
Omalizumab vs Placebo for Omalizumab: serious adverse events	4 of 120	1 of 60	180	NCT03881696	Trial comparisons
Group A (300 mg Maintenance Dose) vs Group B (1200 Maintenance Dose): deaths from any cause	0 of 30	0 of 30	60	NCT03181009	Trial comparisons
Group A (300 mg Maintenance Dose) vs Group B (1200 Maintenance Dose): serious adverse events	0 of 30	0 of 30	60	NCT03181009	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38407394	RESULT	1	PubMed
37087097	RESULT	1	PubMed
35014049	RESULT	1	PubMed
41651410	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001243

GET https://conductscience.org/api/diseases/v1/EFO_1001243/drugs

API reference For AI assistants